I've been working on a response to some jackass on
I've been working on a response to some jackass on stocktwits about the MOA. They think Ohm is wrong about it. Here's what I have so far. Let me know what you think...
That was based on the original inventors premise and it's wrong. When leronlimab was originally invented a lot less was known about the CCR receptors. I think they based that on he fact that there was still immune activity so they thought the chemokines were not being blocked, not realizing that immune activity would still occur through the other receptors. I was the first one to point out that they were wrong and Dr. Recknor told me they were looking into the MOA and biomarkers.
My conclusion that it was wrong is very simple logic. If leronlimab allowed chemokine binding and regular immune activation it would have no activity against overinflammation and autoimmunity. The fact that both the chemokines and leronlimab bind to the n terminus and the chemokines cannot attach when leronlimab is already there is a straightforward proposition.
My thesis for how it's actually working I believe is the correct one. We know that all of the CCR receptors increase when an immune or injurious challenge is presented. CCR5 is by far the most prolific CCR receptor and is the main CCR mechanism in the immune system. The other receptors are mainly backups to it.
You have elevated CCR receptors, elevated chemokine levels and an overinflammatory/autoimmune response mainly due to the CCR5 receptor but also a lower level from the other CCR receptors. The other CCR receptors response in a normal state would be very low. In the elevated state of high immune response those other receptors would equate to a normal immune response due to increased expression. But then you have the CCR5 receptor on top of it with a massive immune response causing disarray. Effectively block the CCR5 receptor and only the normal level of immune response from the other receptors is left. In other words immune homeostasis.
6
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...
Continue Reading
Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...
Continue Reading
Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...
Continue Reading
New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...
Continue Reading
A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...
Continue Reading
LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...
Continue Reading
Univers Sets Sights on Global Physical AI Expansion Now here's a tune we've been humming for a while—AI is coming to take over the mundane, and Univers seems to think it's got the right band together to make that a full-blown concert in the built environment. Announced right in the heart of Antalya, Türkiye, at the esteemed COP31, we're seeing Univers grab hands with...
Continue Reading
Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...
Continue Reading
Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...
Continue Reading
Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...
Continue Reading
Top 5 Most Recently Viewed Articles
Revolutionizing Patient Monitoring with AI Technology BD (Becton, Dickinson and Company) (NYSE: BDX) has introduced a groundbreaking hemodynamic monitoring solution known as the HemoSphere Alta™ Advanced Monitoring Platform. This innovative system incorporates predictive algorithms powered by artificial intelligence (AI), designed to assist clinicians in managing blood...
Continue Reading
Texas Representative James Talarico's Critique of Billionaire Wealth Rep. James Talarico from Texas has recently made headlines with his pointed criticism of Tesla's CEO, Elon Musk, regarding the approval of his staggering new trillion-dollar compensation package. Talarico emphasized the pressing issue of income disparity in the wealthiest nation. The Inequity in Wealth...
Continue Reading
Recent Surge in Priority Technology Holdings Stock Priority Technology Holdings, Inc. (PRTH) has made headlines recently as its stock reached a remarkable 52-week high, hitting $9.89. This surge exemplifies a dramatic turnaround for the company, with its stock value experiencing a striking climb over the past year. Investors have been vigilant about PRTH's trajectory, and...
Continue Reading
Introducing New Homes at Jackson Creek Lokal Homes, a renowned homebuilder in Colorado, is thrilled to announce the upcoming launch of its latest community, Jackson Creek. Nestled in stunning foothills, this new community promises to bring exceptional living spaces to prospective homebuyers. The grand opening is set for a future date, and it is already generating...
Continue Reading
The Factors Behind Hims & Hers Health's Stock Decline Hims & Hers Health Inc shares have faced a downturn in trading, largely influenced by market dynamics involving competitors. The decline appears to be a reaction to news surrounding Eli Lilly and Company, a major player in the pharmaceutical sector. Recent Developments with Eli Lilly Recent announcements from the U.S....
Continue Reading